# Nanome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanome

- Industry: Software
- Headquarters: San Diego, US
- Website: www.nanome.ai
- Total disclosed funding: $1.7M
- Latest round: Seed (Jul 1, 2019)
- Investors on record: 4

## About

Nanome Inc. is a technology company specializing in virtual reality platforms that enhance drug design and molecular visualization for research teams worldwide.Founded in 2015 in San Diego, US, Nanome Inc. offers innovative solutions for drug design. The company received USD 3.00 mn in venture funding in February 2021, led by Bullpen Capital, with participation from Formic Ventures. CEO Steve McCloskey continues to lead the company, which has successfully completed three funding deals to date.Nanome primarily offers an advanced virtual reality (VR) platform designed for drug design and molecular visualization. Its core products include Nanome XR, enabling scientists to analyze molecular structures in three dimensions, and MARA, an AI-assisted conversational interface for data management across global research teams. These tools facilitate communication of ligand design ideas and visualizing molecular interactions for academic institutions, biopharmaceutical companies, and research organizations, enhancing collaborative drug discovery and streamlining complex data visualization.Nanome generates revenue through a subscription-based model for its flagship products, Nanome XR and MARA, catering to pharmaceutical companies, academic institutions, and research organizations. The company structures transactions around annual or monthly fees for access to its high-fidelity VR tools and AI-driven data management. Partnerships may provide tailored solutions for specific drug discovery workflows, enhancing revenue streams through innovative features like collaborative editing and advanced analytics.Following its recent funding of USD 3.00 mn in February 2021, Nanome Inc. plans to establish new business partnerships, build its brand, and expand its science and engineering teams. The company is focused on developing new products and expanding into North America, Europe, and Asia to enhance its market presence. Efforts will be directed towards launching innovative solutions aimed at improving collaboration in drug discovery processes.

## Funding rounds

- Seed, Jul 1, 2019, $0.9M — Colopl Next
- Seed, Mar 1, 2017, $0.8M — Keshif Ventures, Vive X, Sparkland Capital

## Investors

- Keshif Ventures (https://capitalatlas.ai/funds/keshif-ventures) — Seed
- Vive X (https://capitalatlas.ai/funds/vive-x) — Seed
- Sparkland Capital (https://capitalatlas.ai/funds/sparkland-capital) — Seed
- Colopl Next (https://capitalatlas.ai/funds/colopl-next) — Seed